Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d

Journal of Molecular Biology

Volumn 346, Issue 3, 2005, Pages 845-858

  Hannan, Jonathan P ^a   Young, Kendra A ^a   Guthridge, Joel M ^b   Asokan, Rengasamy ^a   Szakonyi, Gerda ^a   Chen, Xiaojiang S ^a   Holers, V Michael ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Complement; Flow cytometry; Mutagenesis; Short consensus repeats; Tetramers

Indexed keywords

BIOTIN; COMPLEMENT COMPONENT C3D; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR TYPE 2; CYSTEINE; DIMER; EPITOPE; FLUOROCHROME; MUTANT PROTEIN; PEPTIDE; PROTEIN; STREPTAVIDIN; TETRAMER; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CELL STRAIN; CELL SURFACE; CRYSTAL STRUCTURE; ERYTHROLEUKEMIA CELL; FLOW CYTOMETRY; GLYCOSYLATION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 13844255020     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.12.007     Document Type: Article

References (39)

1. M.B. Pepys Role of complement in induction of antibody-production in vivo-effect of cobra factor and other C3 reactive agents on thymus-dependent and thymus-independent antibody-responses J. Expt. Med. 140 1974 126 145
2. J.M. Ahearn, and D.T. Fearon Structure and function of the Complement Receptors, CR-1 (CD35) and CR-2 (CD21) Advan. Immunol. 46 1989 183 219
3. P.W. Dempsey, M. Allison, S. Akkaraju, C. Goodnow, and D.T. Fearon C3d of complement as a molecular adjuvant: bridging innate and acquired immunity Science 271 1996 348 350
4. M.C. Carroll, and M.B. Fischer Complement and the immune response Curr. Opin. Immunol. 9 1997 64 69
5. D.T. Fearon The complement system and adaptive immunity Semin. Immunol. 10 1998 355 361
6. J.M. Ahearn, M.B. Fischer, D.A. Croix, S. Georg, M. Ma, and J. Xia Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen Immunity 4 1996 251 262
7. D.A. Croix, J.M. Ahearn, A.M. Rosengard, S. Han, G. Kelsoe, M. Ma, and M.C. Carroll Antibody response to a T-dependent antigen requires B cell expression of complement receptors J. Expt. Med. 183 1996 1857 1864
8. H. Molina, V.M. Holers, B. Li, Y.-F. Fang, S. Mariathasan, and F. Goellner Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2 Proc. Natl Acad. Sci. USA 93 1996 3357 3361
9. J.J. Weis, T.F. Tedder, and D.T. Fearon Identification of a 145,000 Mr membrane-protein as the C3d receptor of (CR-2) of human lymphocytes-B Proc. Natl Acad. Sci. USA 81 1984 881 885
10. K.R. Kalli, J.M. Ahearn, and D.T. Fearon Interactions of iC3b with recombinant isotypic and chimeric forms of CR2 J. Immunol. 147 1991 590 594
11. J.-P. Aubry, S. Pochon, P. Graber, K.U. Jansen, and J.-Y. Bonnefoy CD21 is a ligand for CD23 and regulates IgE production Nature 358 1992 505 507
12. J.-P. Aubry, S. Pochon, J.F. Gauchat, A. Nueda-Marin, V.M. Holers, and P. Graber CD23 interacts with a new functional extracytoplasmic domain involving N-linked oligosaccharides J. Immunol. 152 1994 5806 5813
13. A.X. Delcayre, F. Salas, S. Mathur, K. Kovats, M. Lotz, and W. Lernhardt Epstein-Barr Virus complement C3d receptor is an interferon-alpha receptor EMBO J. 10 1991 919 926
14. J.D. Fingeroth, J.J. Weis, T.F. Tedder, J.L. Strominger, P.A. Biro, and D.T. Fearon Epstein-Barr Virus receptor of human lymphocytes-B is the C3d receptor CR-2 Proc. Natl Acad. Sci. USA 81 1984 4510 4514
15. G.R. Nemerow, R. Wolfert, M.E. McNaughton, and N.R. Cooper Identification and characterization of the Epstein-Barr Virus receptor on human lymphocytes-B and its relationship to the C3d complement receptor (CR-2) J. Virol. 55 1985 347 351
16. G. Szakonyi, J.M. Guthridge, D. Li, K. Young, V.M. Holers, and X.S. Chen Structure of complement receptor 2 in complex with its C3d ligand Science 292 2001 1725 1728
17. A.E. Prota, D.R. Sage, T. Stehle, and J.D. Fingeroth The crystal structure of human CD21: implications for Epstein-Barr virus and C3d binding Proc. Natl Acad. Sci. USA 99 2002 10641 10646
18. B. Nagar, R.G. Jones, R.J. Diefenbach, D.E. Isenman, and J.M. Rini X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2 Science 280 1998 1277 1281
19. J.M. Guthridge, J.K. Rakstang, K.A. Young, J. Hinshelwood, M. Aslam, and A. Robertson Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg Biochemistry 40 2001 5931 5941
20. H.E. Gilbert, J. Hannan, V.M. Holers, and S.J. Perkins Synchroton X-ray scattering and ultracentrifugation of unbound CR2 SCR1-2 shows that SCR-1 and SCR-2 form a family of extended V-shapes in solution Mol. Immunol. 41 2004 235
21. M.D. Moore, R.G. DiScipio, R.N. Cooper, and G.R. Nemerow Hydrodynamic, electron microscopic and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2) J. Biol. Chem. 264 1989 20576 20582
22. G. Zanotti, A. Bassetto, R. Battistutta, C. Folli, P. Arcidiaco, M. Stoppini, and R. Berni Structure at 1.44 Å resolution of an N-terminally truncated form of the rat serum complement C3d fragment Biochim. Biophys. Acta 1478 2000 232 238
23. L. Clemenza, and D. Isenman Structure-guided identification of C3d residues essential for its binding to Complement Receptor 2 (CD21) J. Immunol. 165 2000 3839 3848
24. M.R. Sarrias, S. Franchini, G. Canziani, E. Argyropoulos, W.T. Moore, A. Sahu, and J.D. Lambris Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligand C3d, iC3b, and the EBV glycoprotein gp350/220 J. Immunol. 167 2001 1490 1499
25. C.A. Lowell, L.B. Klickstein, R.H. Carter, J.A. Mitchell, D.T. Fearon, and J.M. Ahearn Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor 2 J. Expt. Med. 170 1989 1931 1946
26. J.-C. Carel, B.L. Myones, B. Frazier, and V.M. Holers Structural requirements for C3dg/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection J. Biol. Chem. 265 1990 12293 12299
27. H. Molina, C. Brenner, S. Jacobi, J. Gorka, J.-C. Carel, T. Kinsohita, and V.M. Holers Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides: at least two distinct sites are necessary for ligand-receptor interaction J. Biol. Chem. 266 1991 12173 12179
28. H. Molina, S.J. Perkins, J. Guthridge, J. Gorka, T. Kinoshita, and V.M. Holers Characterization of a Complement Receptor 2 (CR2/CD21) ligand binding site for C3 J. Immunol. 154 1995 5426 5435
29. T.F. Tedder, L.T. Clement, and M.D. Cooper Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody J. Immunol. 133 1984 678 683
30. S.E. Henson, D. Smith, S.A. Boackle, V.M. Holers, and D.R. Karp Generation of recombinant C3dg tetramers for the analysis of CD21 binding and function J. Immunol. Methods 258 2001 97 109
31. D.R. Martin, A. Yuryev, K.R. Kalli, D.T. Fearon, and J.M. Ahearn Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2 J. Expt. Med. 174 1991 1299 1311
32. D. Morikis, and J.D. Lambris The electrostatic nature of C3d-complement receptor 2 association J. Immunol. 172 2004 7537 7547
33. S.A. Boackle, V.M. Holers, X. Chen, G. Szakonyi, D.R. Karp, E.K. Wakeland, and L. Morel Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein Immunity 15 2001 775 785
34. H.E. Gilbert, J.T. Eaton, J.P. Hannan, V.M. Holers, and S.J. Perkins Solution structure of the complex between CR2 SCR1-2 and C3d human complement: an X-ray scattering and sedimentation modeling study J. Mol. Biol. 346 2005 859 873
35. I. Esparza, J.D. Becherer, J. Alsenz, A. De la Hera, Z. Lao, D.C. Tsoukas, and J.D. Lambris Evidence for multiple sites of interaction in C3 for complement receptor 2 (C3d/EBV receptor, CD21) Eur. J. Immunol. 21 1991 2829 2838
36. T. Selzer, S. Albeck, and G. Schreiber Rational design of faster associating and tighter binding protein complexes Nature Struct. Biol. 7 2000 537 541
37. C. Kiel, T. Selzer, Y. Shaul, G. Schreiber, and C. Herrmann Electrostatically optimized Ras-binding Ral guanine dissociation stimulator mutants increase the rate of association by stabilizing the encounter complex Proc. Natl Acad. Sci. USA 101 2004 9223 9228
38. J.D. Fingeroth, M.L. Clabby, and J.D. Strominger Characterization of a lymphocyte-T Epstein-Barr virus C3d receptor (CD21) J. Virol. 62 1988 1442 1447
39. R. Koradi, M. Billeter, and K. Wüthrich MOLMOL: a program for display and analysis of macromolecular structures J. Mol. Graph. 14 1996 51 55